Intramuscular administration of morphine reduces mustard-oil-induced craniofacial-muscle pain behavior in lightly anesthetized rats

Eur J Pain. 2008 Apr;12(3):361-70. doi: 10.1016/j.ejpain.2007.07.002. Epub 2007 Sep 4.

Abstract

The present study investigated the role of peripheral opioid receptors in mustard oil-induced nociceptive behavior and inflammation in the masseter muscles of lightly anesthetized rats. Experiments were carried out on male Sprague-Dawley rats weighing between 300 and 400 g. After initial anesthesia with sodium pentobarbital (40 mg/kg, i.p.), one femoral vein was cannulated and connected to an infusion pump for the intravenous infusion of sodium pentobarbital. The rate of infusion was adjusted to provide a constant level of anesthesia. Mustard oil (MO, 30 microl) was injected into the mid-region of the left masseter muscle via a 30-gauge needle. Intramuscularly-administered morphine significantly reduced shaking behavior but not MO-induced inflammation. Intramuscular pretreatment with naloxone, an opioid receptor antagonist, reversed antinociception produced by intramuscularly-administered morphine, while intracisternal administration of naloxone did not affect the antinociception of peripheral morphine. Pretreatment with d-Pen-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP), a mu opioid receptor antagonist, but not naltrindole, a delta opioid receptor antagonist, nor norbinaltorphimine (nor-BNI), a kappa opioid receptor antagonist, reversed intramuscularly-administered morphine-induced antinociception. These results indicate that intramuscularly-administered morphine produces antinociception in craniofacial muscle nociception and that this intramuscularly-administered morphine-induced antinociception is mediated by a peripheral mu opioid receptor. Our observations further support the clinical approach of administering opioids in the periphery for the treatment of craniofacial muscle nociception.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / administration & dosage
  • Analgesics / pharmacology
  • Analgesics / therapeutic use*
  • Anesthesia, General
  • Animals
  • Inflammation / chemically induced
  • Injections
  • Injections, Intramuscular
  • Male
  • Masseter Muscle / drug effects
  • Masseter Muscle / physiopathology*
  • Morphine / administration & dosage
  • Morphine / pharmacology
  • Morphine / therapeutic use*
  • Mustard Plant / toxicity*
  • Naloxone / pharmacology
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacology*
  • Nociceptors / drug effects
  • Nociceptors / physiology
  • Pain / chemically induced
  • Pain / physiopathology
  • Pain / prevention & control*
  • Plant Oils / administration & dosage
  • Plant Oils / toxicity*
  • Psychomotor Performance / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Opioid, delta / antagonists & inhibitors
  • Receptors, Opioid, kappa / antagonists & inhibitors
  • Receptors, Opioid, mu / antagonists & inhibitors
  • Single-Blind Method
  • Somatostatin / analogs & derivatives
  • Somatostatin / pharmacology

Substances

  • Analgesics
  • Narcotic Antagonists
  • Plant Oils
  • Receptors, Opioid, delta
  • Receptors, Opioid, kappa
  • Receptors, Opioid, mu
  • phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide
  • Naloxone
  • norbinaltorphimine
  • Somatostatin
  • Naltrexone
  • Morphine
  • naltrindole
  • mustard oil